Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    1.00 (4.65%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Corporate update

19 Jun 2008 07:00

RNS Number : 0476X
Sareum Holdings PLC
19 June 2008
 



19 June 2008

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Corporate Update

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, announced on 2 May 2008, that the Board was undertaking a strategic review to consider how best to take the business forward and create value for shareholders. 

 

On 14 May, the Company announced that as part of the strategic review, the board had implemented a staff restructuring process to reduce its cost base by approximately one third and prepare itself for any potential acquisition or re-financing whilst the future business strategy is under consideration. The restructuring programme has been successfully completed and the Sareum board will continue to review the Company's cost base diligently. In addition, the Company is making progress on a number of fronts and these are described below.

Following announcement of the review on 2 May, Sareum has received expressions of interest in parts or all of its business, particularly its valuable drug discovery programmes, and has received interest in and possible offers to partner, fund, acquire or invest in certain of its programmes or assets. Any transaction resulting from these discussions would lead to an injection of cash into the Company. Initial due diligence is currently being undertaken in respect of several of these discussions. These discussions are at various stages and there is no certainty that any one of them will lead to an offer being made for the Company or any of its assets. The Sareum board continues to actively progress discussions and further announcements will be made as appropriate. 

The Board has concluded, as a result of this review, that the Company should undertake a strategic transaction and it will need to effect a fundraising to enable it to complete such a transaction. In order to facilitate this, the Company will shortly be sending a notice to shareholders convening a general meeting at which shareholders will be asked to give the directors authority to issue further shares for cash. Should the Board decide within a short timescale that strategic transaction is not achievable, the Board will take a decision as to the future of the Company in its present form, as the Company would not be able to continue operations without a significant fundraising.

- Ends-

For further information please contact

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer

 

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 

 

Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett, Colin Aaronson

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQVLFFVQBZBBD
Date   Source Headline
19th Jun 20087:00 amRNSCorporate update
14th May 20087:00 amRNSRestructuring
2nd May 20087:01 amRNSStrategic Review
24th Apr 200811:07 amRNSNotification of Shareholder
14th Apr 20089:26 amRNSFundraising
10th Apr 20087:01 amRNSPresentation at AACR
31st Mar 20087:00 amRNSExtension of Collaboration
6th Mar 20087:01 amRNSResearch Update
6th Mar 20087:00 amRNSInterim Results
4th Feb 20087:00 amRNSNotice of Results
30th Nov 20077:00 amRNSTotal Voting Rights
19th Nov 20077:00 amRNSDirector/PDMR Shareholding
16th Nov 20077:01 amRNSBoard Appointment
15th Nov 20073:07 pmRNSPlacing of Shares
15th Nov 200712:59 pmRNSAGM Statement
31st Oct 20073:58 pmRNSTotal Voting Rights
26th Oct 20074:35 pmRNSDirector/PDMR Shareholding
24th Oct 200712:24 pmRNSPlacing of shares
22nd Oct 20077:01 amRNSFundraising
16th Oct 20074:33 pmRNSAnnual Report and AGM notice
8th Oct 200711:01 amRNSHolding(s) in Company
2nd Oct 20077:01 amRNSResearch Update
2nd Oct 20077:01 amRNSPreliminary Results
21st Sep 20077:01 amRNSDirectorate Change
13th Sep 20079:42 amRNSNotice of Results
16th Aug 20077:00 amRNSDisclosure of Information
30th Jul 20077:02 amRNSExtention of Collaboration
18th Jun 200712:34 pmRNSDirectorate Change
15th May 20077:01 amRNSCancer Program Update
6th Feb 20077:02 amRNSResearch Programme Update
6th Feb 20077:01 amRNSInterim Results
31st Jan 200711:08 amRNSTotal Voting Rights
22nd Jan 20077:01 amRNSCollaboration with J&J
12th Jan 20077:00 amRNSNotice of Results & Update
8th Jan 20077:00 amRNSNew Investment in Sareum
18th Dec 20064:39 pmRNSTotal Voting Rights
20th Nov 20067:01 amRNSAgreement with Genentech
30th Oct 20064:23 pmRNSIssue of Equity
19th Oct 20065:40 pmRNSBoard Change
19th Oct 200610:43 amRNSAGM Statement
9th Oct 20067:00 amRNSSignificant Collaboration
26th Sep 20067:01 amRNSRoche Cancer Collaboration
25th Sep 20064:37 pmRNSPosting of accounts
4th Sep 20067:03 amRNSPreliminary Results
31st Aug 20067:01 amRNSCancer Drug Collaboration
15th Aug 20067:01 amRNSCollaboration with Lundbeck
13th Jul 20067:01 amRNSExtension of Collaboration
20th Jun 20067:03 amRNSCollaboration with Sirtris
14th Jun 20069:45 amRNSHolding(s) in Company
8th Jun 20067:00 amRNSSuccess with Schering AG

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.